Wedge Capital Management L L P NC Has $28.03 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Wedge Capital Management L L P NC trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,447 shares of the biotechnology company's stock after selling 10,132 shares during the period. Wedge Capital Management L L P NC owned 0.18% of United Therapeutics worth $28,032,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. American Century Companies Inc. lifted its holdings in United Therapeutics by 42.8% in the 2nd quarter. American Century Companies Inc. now owns 41,233 shares of the biotechnology company's stock worth $13,135,000 after purchasing an additional 12,360 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in shares of United Therapeutics by 12.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 48,981 shares of the biotechnology company's stock worth $15,603,000 after buying an additional 5,531 shares during the period. Dimensional Fund Advisors LP grew its stake in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company's stock valued at $186,656,000 after buying an additional 22,683 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in United Therapeutics by 16.9% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 13,918 shares of the biotechnology company's stock worth $4,433,000 after acquiring an additional 2,013 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its holdings in United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock valued at $652,000 after acquiring an additional 33 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Trading Down 2.0 %

Shares of United Therapeutics stock traded down $7.46 during mid-day trading on Friday, reaching $358.93. 248,342 shares of the stock were exchanged, compared to its average volume of 267,993. The company has a market cap of $16.03 billion, a price-to-earnings ratio of 15.76, a price-to-earnings-growth ratio of 0.93 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The firm has a 50-day simple moving average of $367.40 and a 200 day simple moving average of $353.73.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.38 EPS. On average, research analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Activity

In related news, CFO James Edgemond sold 7,782 shares of the stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the transaction, the chief financial officer now directly owns 6,426 shares in the company, valued at $2,358,277.74. This represents a 54.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 144,630 shares of company stock valued at $54,371,916 over the last three months. 11.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on UTHR. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. HC Wainwright upped their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Argus boosted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $378.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.